pindolol has been researched along with Pulmonary Fibrosis in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Musk, AW | 1 |
| Pollard, JA | 1 |
| Krupp, P | 1 |
| Crawford, JM | 1 |
2 other studies available for pindolol and Pulmonary Fibrosis
| Article | Year |
|---|---|
Pindolol and pulmonary fibrosis.
Topics: Humans; Lung; Male; Middle Aged; Pindolol; Pulmonary Fibrosis | 1979 |
Pindolol and pulmonary fibrosis.
Topics: Humans; Pindolol; Pulmonary Fibrosis | 1979 |